Recent Flatiron Health research published in Journal of Clinical Pathways found integrating evidence-based pathways into ordering workflows may improve pathway adherence, previously associated with equal or better survival outcomes in similar cancer diagnoses. In an increasingly complex healthcare ecosystem—facing headwinds like dynamic payment models, rapid therapeutic advancements, and workforce shortages—oncologists and their patients are in need of intuitive, EHR embedded technology solutions like Flatiron Assist™ that increase efficiency and enable flexibility for innovative care delivery. Visit our website a link to the full publication and to learn more about why this matters ⬇️ http://spkl.io/6045fB8Mx
Flatiron Health
Biotechnology Research
New York, New York 77,455 followers
Reimagining the infrastructure of cancer care
About us
Flatiron Health’s mission is to improve and extend lives by learning from the experience of every person with cancer.
- Website
-
http://www.flatiron.com
External link for Flatiron Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- New York, New York
- Type
- Privately Held
Locations
-
Primary
233 Spring St
5th Floor
New York, New York 10013, US
Employees at Flatiron Health
Updates
-
The #ClinicalPathwaysCongress is just around the corner, and we’re looking forward to discussing how technology is transforming cancer treatment and patient outcomes. Don't miss Flatiron Health at booth #17. Our team is ready to showcase our latest innovations and discuss the future of oncology care. Want to connect with our team members during the conference? Schedule a meeting today: http://spkl.io/6040f6yRr
-
In cases where randomized control trials (RCT) may not be feasible, external control arms (ECAs) using #realworlddata can offer a suitable opportunity to support single arm trials. This collaborative study, recently published in Frontiers in Drug Safety and Regulation, is aimed to understand common sources of bias in ECAs, specifically looking at commonly used oncology endpoints like progression-free survival. Deepening our understanding of proper measurement for and efficacious use of ECAs has the potential to de-risk and accelerate clinical trials when a RCT is not feasible, potentially bringing treatments to patients sooner. Read more for an overview of the publication and a breakdown of why this matters: https://lnkd.in/gBAWR2PR
Measurement error and bias in real-world oncology endpoints when constructing external control arms
resources.flatiron.com
-
At Flatiron Health, we’re filling critical evidence generation gaps with oncology #RWD from the UK, Germany, and Japan and gaining insights from patients with various cancers through global studies that were previously impossible. Access to global real-world data allows us to conduct comparative effectiveness research, improving the precision and effectiveness of targeted therapies and much, much more. Learn more from Head of Outcomes Research & Evidence Generation, Blythe Adamson, PhD, MPH ⬇️
-
“The amount of evidence we need to generate as an industry is way out of alignment with what we can actually supply." Despite this imbalance, all hope is not lost. There is a critical role that technology can play in evidence generation. Flatiron’s Director of Clinical Operations, Josh Buddle, discusses the use of technology as part of prospective #evidencegeneration in this interview with Research Revolution: http://spkl.io/6041f6ypD
-
ANNOUNCED TODAY: Flatiron Health will be attending the 2024 International Association for the Study of Lung Cancer World Conference on Lung Cancer, showcasing how our evidence solutions can be leveraged to bolster lung cancer research across the product development lifecycle. Learn more about how Flatiron is unlocking critical insights in lung cancer research with panoramic data with maximum cohort sizes of over 290K lung cancer patients. #WCLC24 https://lnkd.in/eXahWcYv
Flatiron Health at WCLC 2024 | Real-World Evidence Research
events.flatiron.com
-
Can we re-evaluate the approach to data acquisition for #clinicaltrials for the sake of timelines and our teams? Hear from our Director of Clinical Operations, Josh Buddle, as he reflects on a topic we evaluate frequently as part of prospective evidence generation: the role of data in post-marketing trials. Watch the full episode with Research Revolution here: http://spkl.io/6041f6yT1
-
The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.
-
Spearheaded by Friends of Cancer Research, a research collaboration between #RWD providers, pharmaceutical companies, academics, researchers, and experts from government agencies was recently published in JCO Clinical Cancer Informatics ⤵️ #RWEFriends As use of #RWD to support drug development and regulatory decision-making continues to be prioritized, aligning on methodologies for aggregating and analyzing this data is critical to ensure it is a reliable and consistent source of information. Using data from 7 RWD partners, including Flatiron Health, the researchers found RWD has the ability to increase understanding of therapies effectiveness, including when specific populations are underrepresented in clinical trials or to identify populations for future trials or label expansions on already approved therapies. For more on this research and why is matters, visit our website: http://spkl.io/6043f6ZHS
Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy
resources.flatiron.com
-
Flatiron Health will be leading discussions on key innovations and the future of oncology care at the upcoming Clinical Pathways Congress + Cancer Care Business Exchange Experts James Hamrick, Will Shapiro, Rebecca Maniago, PharmD, BCOP, and Nina Chavez will be participating in 3 key panels: - Digital Innovation: Cancer-Specific #AI Use Cases - How to Build Your Own Pathway Program - Strategies for Patient Navigation Services To connect directly with our team onsite, visit us at booth #17 or schedule a meeting today: https://lnkd.in/egnYrU-g #CPC_CBEx